Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSuNaMI-II in very preterm ventilated infants at risk of neonatal chronic lung disease
2011-000811-23Phase 4Unknown
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of Poractant alfa in bronchopulmonary dysplasia (BPD) and chronic lung disease (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Development and severity of neonatal chronic lung disease. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
bronchopulmonary dysplasia (BPD)chronic lung disease
Beyond the preview
Go deeper on 2011-000811-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000811-23.